No black box warning on record for Evotaz

As of the latest FDA labeling reviewed, Evotaz (ATAZANAVIR AND COBICISTAT) does not carry a black box warning. Standard warnings and precautions still apply — see the full Evotaz medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Cardiac conduction abnormalities: PR interval prolongation may occur in some patients. Consider ECG monitoring in patients with preexisting conduction system disease or when administered with other drugs that may prolong the PR interval. ( 5.1 , 6 , 7.3 , 12.2 , 17 ) • Severe skin reactions: Discontinue if severe rash develops. ( 5.2 , 6.1 , 17 ) • Assess creatinine cl

No black box warning on record for Evotaz

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Cardiac conduction abnormalities: PR interval prolongation may occur in some patients. Consider ECG monitoring in patients with preexisting conduction system disease or when administered with other drugs that may prolong the PR interval. ( 5.1 , 6 , 7.3 , 12.2 , 17 ) • Severe skin reactions: Discontinue if severe rash develops. ( 5.2 , 6.1 , 17 ) • Assess creatinine cl

Evotaz Black Box Warning

No black box warning on record for Evotaz

Other warnings & precautions

Evotaz Black Box Warning

No black box warning on record for Evotaz

Other warnings & precautions